
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Pharmaceutical Preparations · market cap $329M
Research and calibrated estimates, not financial advice — verify before acting.
| Asset | Phase | Indication |
|---|---|---|
| ofloxacin | Phase 3 | Diabetic Foot Ulcers |
| EB-101 | Phase 3 | Epidermolysis Bullosa |
| EB-101 Surgical application of RDEB wounds | Phase 3 | Epidermolysis Bullosa |
| MSI-78 | Phase 3 | Diabetic Foot Ulcers |
| EcoNail™ (econazole 5%/SEPA® 18% nail lacquer) | Phase 2 | Onychomycosis |
| LZRSE-Col7A1 Engineered Autologous Epidermal Sheets | Phase 2 | Epidermolysis Bullosa Dystrophica |
Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
See ProApproval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.